Pieris Q1 net loss widens to $13.2M; elarekibep Phase 2a data expected mid-2024

PALVELLA THERAPEUTICS, INC.

Q1 2023 net loss of $13.2M ($0.45/share) vs. $5.1M ($0.07) in Q1 2022; cash $48.4M.
Elarekibep Phase 2a enrollment ongoing; topline data by mid-2024; AstraZeneca adding sites and geographies.
PRS-220 Phase 1 results expected H2 2023; PRS-400 toward candidate nomination H2 2023.
Cinrebafusp alfa in 2L+ HER2+ gastric cancer: 100% ORR in 5 patients; enrollment stopped for strategic reasons.
Seagen initiated Phase 1 for SGN-BB228 (CD228/4-1BB); $5M milestone paid.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALVELLA THERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-013408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.